A new research by scientists at Cold Spring Harbor Laboratory reveals that chemicals which are used to target certain enzymes can be developed into drugs that further provide an opportunity to develop therapies against some aggressive leukemias. The findings of the study are published in the journal Molecular Cell.
MEF2C is a transcription factor--a regulatory protein that helps control the activity of certain genes. Its overactivity is implicated in about 15% of cases of acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow that is often fatal.
CSHL Associate Professor Christopher Vakoc, M.D., Ph.D., and colleagues now report that they can stop the growth of MEF2C-driven AML cells by blocking either of two target enzymes, known as LKB1 and salt-inducible kinase. The chemicals that the team used to interfere with the enzymes are small molecules that have the potential to be developed into drugs, Vakoc says.
Led by Yusuke Tarumoto, a postdoctoral researcher in Vakoc's lab, the team has now deployed that technology against AML. Their screens revealed that LKB1 and salt-inducible kinase are critical for the survival of certain AML cells. The enzymes had not previously been linked to AML, but with further experiments, the team learned that both help control the MEF2C transcription factor, which is a known cancer promoter.
"At the end of project, we realized we'd had actually discovered a way to control a transcription factor," says Vakoc. That's exciting, he says, because while most leukemias are thought to be caused by wayward transcription factors, such proteins are among the most challenging to target with drugs.
The chemicals the team used to switch off LKB1 and salt-inducible kinase in their lab-grown cancer cells are not suitable as therapeutic compounds, but Vakoc is optimistic that it will be possible to develop drugs that target these enzymes. Animal experiments are already under way in his lab to begin to investigate the strategy as a potential treatment approach.